NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q2 | -1.69 | $0 | -$2M |
| 2024 Q1 | -2.46 | $0 | -$2M |
| 2023 Q4 | -5.03 | $2M | -$55M |
| 2023 Q3 | -9.40 | $0 | -$7M |
| 2023 Q2 | -7.25 | $0 | -$6M |
| 2023 Q1 | -9.17 | $0 | -$12M |
| 2022 Q4 | -17.43 | $0 | -$11M |
| 2022 Q3 | -14.96 | $0 | -$12M |